Maybe a TIA is a Gr 2 Mace?

Happy to discuss over a drink!
Can’t wait for #ESTRO24

Yup same operation used for over 40 years. The robot makes ergonomic differences but data suggests its surgeon volume (not the machine) that improves outcomes.

Cf RT for #ProstateCa has been revolutionized.
1990’s: 33+ tx, >50+ BF
2018: 5 tx, 3.5% BF
2028: 2 tx, 🟰BF, ⬆️ QOL?

Looked like a great conference! Wish I was there. Will plan for next year.

I’m sure you’re right and I’m embarrassed that I was surprised when we published this. It’s a slide I use a lot as it really emphasises the importance of collecting patient reported outcomes.

Why wasn’t ARAT an option?

With #PROFOUND I’m not convinced an antagonist is safer than an agonist (where CV health is optimized). But Wallach’s RWE also didn’t show a difference in MACE events. Not sure why #HERO showed a big difference… type 1 error!?! What do others think?

Interesting Q Chad Tang, MD … sounds like a great study‼️

Have you designed it? If so what’s the name. Amar Kishan will tell you it’s all about the study name!

I think we all worry about compliance. But you can check a patients T to confirm compliance (otherwise switch them to Ag)

Ian Davis Dr. Andrew Loblaw Daniel E Spratt Chris Parker Shankar Siva Amar Kishan Does anyone else wonder whether patient compliance (for understandable reasons) may confuse therapy duration/effect?

💯 agree Ian Davis

I hate to say it but “more studies needed”. However for UIR I do t think we’ll ever be able to have a trial large enough to answer this question (nor is it the most important Q in that space)

Agree Ian Davis and now that relugolix is now in 🇨🇦 we now struggle with optimal duration of ADT.

If giving 4mo ADT for unfav int risk or 8mo for IAB do we give the same duration of relugolix or 50% longer?

What do you do Daniel E Spratt Chris Parker Shankar Siva Amar Kishan

Vedang Murthy Sean Collins Prostate SBRT@Georgetown University Same phase 2 randomized trial from GETUG,Association Française d'Urologie - AFU.
'' DARIUS '' TRIAL, finished in few months.

✨Efficacy end point with PSA at M6.
✨Genomic and radiomics ancillary studies will be of interest!
✨Pooled data with INTREPID also...Paul Nguyen

It’s a bit shocking but good to see mature salvage RT data. To me the good biochemical control rates emphasize need for ADT (at least short term)

Also with G3+ toxicity near 8% opens the concept of needing spacers and/or tighter margins (MRL or GU-Lok)

We celebrated the retirement of Dr. Norm Laperriere after 40 years Radiation Medicine Program Princess Margaret Cancer Centre @uhn for extraordinary care and research of eye, CNS, & pediatric cancers. Thanks to arjun sahgal Sunnybrook Health Sciences Centre for participating to honor his mentor.

The Cdn Task Force has been “updating” their guidelines over last 2.5y. I’m on the panel.

Interestingly they finished the Breast Cancer screening guidelines after only 6mo (started 2y after the prostate guideline)

It’s been very disappointing.

Show us the data that it is safe and effective. Then we can consider it.

Haha

A number of journals are now taking advantage of researchers with peer-reviewed grants that must publish open access. Its sickening ‼️

Yup!